Niclosamide

• Description :

  Niclosamide (BAY2353) is an orally active antihelminthic agent used in parasitic infection research[1]. Niclosamide is a STAT3 inhibitor with an IC50 of 0.25 μM in HeLa cells[4]. Niclosamide has biological activities against cancer, inhibits DNA replication in Vero E6 cells[2][3][5].

• Product Name Alternative :

  BAY2353

• UNSPSC :

  12352005

• Hazard Statement :

  H400

• Target :

  Antibiotic; Parasite; STAT

• Type :

  Reference compound

• Related Pathways :

  Anti-infection; JAK/STAT Signaling; Stem Cell/Wnt

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Infection; Cancer

• Assay Protocol :

  https://www.medchemexpress.com/Niclosamide.html

• Purity :

  99.96

• Solubility :

  DMF : 5 mg/mL (ultrasonic) |DMSO : 4.55 mg/mL (ultrasonic) |H2O : < 0.1 mg/mL (ultrasonic; warming; heat to 60°C)

• Smiles :

  O=C(NC1=CC=C([N+]([O-])=O)C=C1Cl)C2=CC(Cl)=CC=C2O

• Molecular Formula :

  C13H8Cl2N2O4

• Molecular Weight :

  327.12

• Precautions :

  H400

• References & Citations :

  [1]P Andrews, et al. The biology and toxicology of molluscicides, Bayluscide. Pharmacol Ther. 1982;19 (2) :245-95.|[2]Wei Chen, et al. Niclosamide: Beyond an antihelminthic drug. Cell Signal. 2018 Jan;41:89-96.|[3]Kei Satoh, et al. Identification of Niclosamide as a Novel Anticancer Agent for Adrenocortical Carcinoma. Clin Cancer Res. 2016 Jul 15;22 (14) :3458-66.|[4]Xiaomei Ren, et al. Identification of Niclosamide as a New Small-Molecule Inhibitor of the STAT3 Signaling Pathway. ACS Med Chem Lett. 2010 Sep 7;1 (9) :454-9.|[5]Chang-Jer Wu, et al. Inhibition of severe acute respiratory syndrome coronavirus replication by niclosamide. Antimicrob Agents Chemother. 2004 Jul;48 (7) :2693-6.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Launched

• Isoform :

  STAT3

• CAS Number :

  [50-65-7]